Jeffrey Farrow of Tarsus (TARS) acquires 13,042 shares through RSU settlement

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. officer Jeffrey S. Farrow reported the settlement of vested Restricted Stock Units into common stock. On March 15, 2026, he acquired 13,042 shares of common stock upon exercise/settlement of RSUs granted under the company’s 2020 Stock Plan.

The filing indicates these RSUs were from grants made on March 7, 2024 and March 5, 2025, each vesting in four equal annual installments every March 15, subject to continued service. Following these transactions, Farrow directly holds 49,746 shares of Tarsus common stock.

Insider Trade Summary

13,042 shares exercised/converted

Mixed 3 txns

Insider Farrow Jeffrey S

Role See Remarks

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	8,020	$0.00	--
Exercise	Restricted Stock Units	5,022	$0.00	--
Exercise	Common Stock	13,042	$0.00	--

Holdings After Transaction: Restricted Stock Units — 16,040 shares (Direct); Common Stock — 49,746 shares (Direct)

Footnotes (1)

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrow Jeffrey S

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		13,042	A	(1)	49,746	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/15/2026		M			8,020	(3)	(3)	Common Stock	8,020	$0	16,040	D
Restricted Stock Units	(2)	03/15/2026		M			5,022	(4)	(4)	Common Stock	5,022	$0	15,067	D

Explanation of Responses:

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

2. Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

3. RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

4. RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

Remarks:

Chief Financial Officer and Chief Strategy Officer

	/s/ Jeffrey Farrow	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tarsus Pharmaceuticals (TARS) report for Jeffrey S. Farrow?

Jeffrey S. Farrow received 13,042 shares of Tarsus common stock through settlement of vested Restricted Stock Units. These RSUs converted into shares at no cash exercise price as part of his equity compensation under the company’s 2020 Stock Plan.

How many Tarsus (TARS) shares does Jeffrey S. Farrow hold after this Form 4?

After the reported RSU settlements, Jeffrey S. Farrow directly owns 49,746 shares of Tarsus Pharmaceuticals common stock. This figure reflects his position following the March 15, 2026 derivative exercise and conversion transactions disclosed in the Form 4 filing.

What type of securities did Jeffrey S. Farrow exercise in the Tarsus (TARS) Form 4?

The filing shows exercises of Restricted Stock Units, a form of stock-based compensation. Each RSU represented a contingent right to receive one share of Tarsus common stock, which converted into 13,042 shares upon vesting and settlement on March 15, 2026.

Were the Tarsus (TARS) insider transactions open-market purchases or RSU settlements?

The transactions were RSU settlements, not open-market purchases. Farrow acquired shares at a reported price of $0.00 per share as vested Restricted Stock Units converted into common stock under pre-existing equity award agreements.

When were the RSUs in the Tarsus (TARS) Form 4 originally granted?

The RSUs were granted on March 7, 2024 and March 5, 2025 under the Tarsus Pharmaceuticals 2020 Stock Plan. Each grant vests 25% on March 15 of four consecutive years, subject to Farrow’s continuous service with the company.

How do the Tarsus (TARS) RSU grants for Jeffrey S. Farrow vest over time?

The RSU grants vest in four equal annual installments of 25% each. For the 2024 grant, installments vest on March 15 of 2025, 2026, 2027 and 2028, while the 2025 grant vests on March 15 of 2026, 2027, 2028 and 2029, contingent on continued service.